These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 26988828

  • 1. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
    Liu JJ, Zhang S, Wu CJ, Ma LX, Liu Y, Li H, Cui HX, Cheng Y.
    Zhonghua Zhong Liu Za Zhi; 2016 Mar 23; 38(3):211-7. PubMed ID: 26988828
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec 23; 37(6):864-872. PubMed ID: 29270745
    [Abstract] [Full Text] [Related]

  • 6. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
    Huang LT, Zhang SL, Han CB, Ma JT.
    Lung Cancer; 2022 Apr 23; 166():9-16. PubMed ID: 35151115
    [Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
    Chang JW, Huang CY, Fang YF, Chang CF, Yang CT, Kuo CS, Hsu PC, Wu CE.
    Thorac Cancer; 2023 Jan 23; 14(1):12-23. PubMed ID: 36424878
    [Abstract] [Full Text] [Related]

  • 8. Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study.
    Zhou J, Qin H, Miao J, Liu R, Wang W.
    Medicine (Baltimore); 2023 Jun 30; 102(26):e34110. PubMed ID: 37390279
    [Abstract] [Full Text] [Related]

  • 9. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S, Lee SY, Kim D, Sim YS, Ryu JS, Choi J, Lee SH, Ryu YJ, Lee JH, Chang JH.
    BMC Cancer; 2021 Jan 11; 21(1):52. PubMed ID: 33430803
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 11; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
    Wang Y, Yuan X, Yang M, Shen Z, Chen H, He X, Ma Y, Ding L.
    Pharmacology; 2021 Sep 11; 106(11-12):658-666. PubMed ID: 34673645
    [Abstract] [Full Text] [Related]

  • 18. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, Luo Y, Tang W.
    Eur J Clin Pharmacol; 2016 Jan 11; 72(1):1-11. PubMed ID: 26490356
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.
    Tang M, Wang S, Zhao B, Wang W, Zhu Y, Hu L, Zhang X, Xiong S.
    Med Sci Monit; 2019 Nov 09; 25():8430-8437. PubMed ID: 31704907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.